Leap Therapeutics (NASDAQ:LPTX) was downgraded by equities research analysts at Raymond James from an “outperform” rating to a “market perform” rating in a report issued on Friday, Marketbeat Ratings reports.
Other equities research analysts have also issued reports about the company. Zacks Investment Research lowered Leap Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, October 15th. ValuEngine raised Leap Therapeutics from a “hold” rating to a “buy” rating in a research report on Thursday, August 1st.
Shares of Leap Therapeutics stock traded up $0.04 on Friday, reaching $0.77. 4,267 shares of the company were exchanged, compared to its average volume of 218,344. The stock has a fifty day moving average price of $1.15 and a 200-day moving average price of $1.54. The firm has a market capitalization of $15.59 million, a price-to-earnings ratio of -0.31 and a beta of 2.47. The company has a current ratio of 1.39, a quick ratio of 1.39 and a debt-to-equity ratio of 0.12. Leap Therapeutics has a fifty-two week low of $0.57 and a fifty-two week high of $4.05.
Several hedge funds have recently modified their holdings of LPTX. FMR LLC grew its holdings in shares of Leap Therapeutics by 63.3% during the first quarter. FMR LLC now owns 1,563,124 shares of the company’s stock valued at $2,923,000 after buying an additional 606,000 shares in the last quarter. Bank of New York Mellon Corp purchased a new position in shares of Leap Therapeutics during the second quarter valued at $42,000. BlackRock Inc. grew its holdings in shares of Leap Therapeutics by 40.0% during the second quarter. BlackRock Inc. now owns 34,233 shares of the company’s stock valued at $61,000 after buying an additional 9,782 shares in the last quarter. A.R.T. Advisors LLC purchased a new position in shares of Leap Therapeutics during the second quarter valued at $28,000. Finally, Vanguard Group Inc. grew its holdings in shares of Leap Therapeutics by 183.4% during the second quarter. Vanguard Group Inc. now owns 555,195 shares of the company’s stock valued at $994,000 after buying an additional 359,320 shares in the last quarter. Institutional investors and hedge funds own 11.04% of the company’s stock.
Leap Therapeutics Company Profile
Leap Therapeutics, Inc, a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Its clinical stage programs include DKN-01, a monoclonal antibody that inhibits Dickkopf-related protein 1, which is in Phase I/II clinical trial in patients with esophagogastric, biliary tract, gynecologic, and non-small cell lung cancers, as well as hepatocellular carcinoma, a type of liver cancer.
Featured Story: How Do I Invest in Dividend Stocks
Receive News & Ratings for Leap Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Leap Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.